Vitae Biomedical Co., Ltd. continues to strengthen its global intellectual property (IP) strategy, with multiple patent applications for its lung cancer detection technologies formally accepted across key international markets.

As part of its expanding patent family, a second key patent within its lung cancer detection technology has been formally accepted by patent offices in the United States, Thailand, Indonesia, India, and the European Union. This milestone follows the earlier grant and acceptance of its first-generation detection technology in major markets, marking continued progress in building a comprehensive global IP portfolio.

The company has been actively pursuing international patent protection across multiple regions, including Taiwan, the United States, Japan, Korea, Australia, Singapore, India, and the European Union. Through this broad and coordinated filing strategy, Vitae Biomedical aims to secure both technological leadership and market access in the field of non-invasive cancer diagnostics.

This expanding IP portfolio reflects the company’s ongoing investment in research and development, as well as its commitment to translating innovation into clinically applicable solutions. By protecting key components of its antibody design, assay methodology, and detection platform, Vitae Biomedical is establishing a strong foundation for long-term competitiveness.

As global awareness of early disease detection continues to rise, the company’s patented technologies are positioned to support more accessible, accurate, and scalable cancer screening solutions across diverse healthcare systems.